Literature DB >> 16991106

Brief cognitive assessment of cancer patients: evaluation of the Mini-Mental State Examination (MMSE) psychometric properties.

Kyriaki Mystakidou1, Eleni Tsilika, Efi Parpa, Antonis Galanos, Lambros Vlahos.   

Abstract

AIM: The aim of the present study was to validate the Greek version of the MMSE in advanced-cancer patients attending a palliative care unit.
METHODS: The sample consisted of 103 advanced-cancer patients. The questionnaire was completed at baseline and three days later. Together with the MMSE, the patients also completed the EORTC QLQ-C30 Cognitive functioning scale, while researchers recorded data on demographic characteristics, disease status and treatment regimen.
RESULTS: MMSE had overall Cronbach alpha 0.890. Validity as performed using known-group analysis showed good results. MMSE discriminated well between subgroups of patients differing in disease severity as defined by ECOG performance status. Comparison between the MMSE and the EORTC Cognitive functioning scale was statistically significant (p<0.05).
CONCLUSION: These psychometric properties of the Greek version of the MMSE confirm it as a valid and reliable measure when administered to patients with advanced cancer. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 16991106     DOI: 10.1002/pon.1090

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  9 in total

1.  Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research.

Authors:  Todd Monroe; Michael Carter
Journal:  Eur J Ageing       Date:  2012-06-15

Review 2.  Outcome assessment instruments in palliative and hospice care--a review of the literature.

Authors:  Stephanie Stiel; T Pastrana; C Balzer; F Elsner; C Ostgathe; L Radbruch
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

3.  Collusion: The Facade and its Implications on Total Pain Management in Palliative Care.

Authors:  Bincy Mathew; Bidhu Kalyan Mohanti; Saipriya Tewari; Vedant Kabra; Pushpinder Gulia; Peush Bajpai; Anusheel Munshi
Journal:  Indian J Palliat Care       Date:  2021-02-17

4.  Patients with head and neck cancer: Are they frailer than patients with other solid malignancies?

Authors:  Linda Bras; Daphne A J J Driessen; Julius de Vries; Suzanne Festen; Bernard F A M van der Laan; Barbara L van Leeuwen; Geertruida H de Bock; Gyorgy B Halmos
Journal:  Eur J Cancer Care (Engl)       Date:  2019-09-30       Impact factor: 2.520

5.  Identifying mental health status using deep neural network trained by visual metrics.

Authors:  Somayeh B Shafiei; Zaeem Lone; Ahmed S Elsayed; Ahmed A Hussein; Khurshid A Guru
Journal:  Transl Psychiatry       Date:  2020-12-14       Impact factor: 6.222

6.  Herth Hope Index: A Psychometric Evaluation Study within a Sample of Greek Patients with Cancer.

Authors:  Maria Nikoloudi; Eleni Tsilika; Efi Parpa; Sotiria Kostopoulou; Anastasios Tentolouris; Constantin Psarros; Mantoudi Alexandra; Kyriaki Mystakidou
Journal:  Indian J Palliat Care       Date:  2021-09-29

7.  Selected Domains within a Comprehensive Geriatric Assessment in Older Patients with Non-Hodgkin Lymphoma are Highly Associated with Frailty.

Authors:  María Del Pilar Gamarra Samaniego; Carmelo J Blanquicett; Roger V Araujo Castillo; Julio C Chavez; Brady Ernesto Beltrán Garate
Journal:  Clin Hematol Int       Date:  2022-05-11

8.  Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.

Authors:  Daniel T Barratt; Pål Klepstad; Ola Dale; Stein Kaasa; Andrew A Somogyi
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

9.  A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.

Authors:  Krzysztof Nosek; Wojciech Leppert; Hanna Nosek; Jerzy Wordliczek; Dariusz Onichimowski
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.